Research summaries – Signal Engine

Here we publish source-bound cancer-research summaries produced from Signal Engine deep searches and deep analyses. Deep research has two levels: first-round and second-round. These are not news items and not standalone scientific publications; they are structured syntheses of evidence found in the literature, clinical trials, and experimental research. The system does not diagnose and does not choose treatment.

First-round deep research: mapping literature and clinical evidence. How does the treatment strategy for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer change according to disease biological characteristics, endocrine resistance, prior therapies, and molecular alterations such as ESR1, PIK3CA, AKT1, or PTEN alterations?

2026-09-08

Extracted mechanistic / response-determinant data (in detail, not a HR dump): In the CAPItello-291 trial, capivasertib plus fulvestrant demonstrated a statistically significant progression-free survival benefit in pretr…

Deep Research Round II: Therapeutic Options and Challenges in Advanced Non-Small Cell Lung Cancer Harbouring the KRAS G12A Mutation

2026-09-07

In advanced or metastatic KRAS G12A-mutant NSCLC, there are currently no approved allele-specific targeted agents; first-line management consists of the combination of immunotherapy and chemotherapy, while MEK and RTK c…

Deep Research Round I. What evidence and potential therapeutic pathways are currently available in advanced or metastatic non-small cell lung cancer harbouring a KRAS p.G12A mutation, and why does this mutation pose a particularly difficult therapeutic challenge?

2026-09-07

Retrieved mechanistic / response-determinant data (detailed, not a HR dump): A phase 1/1B study evaluating pembrolizumab and trametinib in advanced KRAS-mutation-enriched NSCLC demonstrated modest clinical activity with…